fpi-2620
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 19, 2022 (NCT05456503)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- 14-3-3 protein thetaBINDING AGENT
YWHAQ binding agent
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05456503 | Phase 3 | Sep 19, 2022 | National Institutes of Health (NIH), University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1